Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office
This article was originally published in The Tan Sheet
Executive Summary
NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26
You may also be interested in...
NCCAM PC-SPES Clinical Research Could Resume With “Clean” Product
NIH's National Center for Complementary & Alternative Medicine could resume funding clinical research on PC-SPES if an independent manufacturer is able to develop an uncontaminated version of the proprietary herbal blend, NCCAM Director Stephen Straus, MD, suggested at the center's advisory council meeting in Rockville, Md. Aug. 26
HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR
NCCAM is looking to fund research on the properties of botanicals used by HIV/AIDS patients, including their potential antiretroviral properties as well as their ability to alleviate the side effects of HIV/AIDS drugs or to interact with such drugs
HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR
NCCAM is looking to fund research on the properties of botanicals used by HIV/AIDS patients, including their potential antiretroviral properties as well as their ability to alleviate the side effects of HIV/AIDS drugs or to interact with such drugs